58759-63-0

Basic information

• Product Name: 2(3H)-Benzothiazolethione,5-nitro-(9CI)
• Synonyms: 2(3H)-Benzothiazolethione,5-nitro-(9CI);5-Nitro-2(3H)-benzothiazolethione;5-Nitro-2-benzothiazolethiol;2(3H)-Benzothiazolethione, 5-nitro-;5-Nitrobenzothiazol-2-thiol;5-nitrobenzo[d]thiazole-2-thiol;5-nitro-2,3-dihydro-1,3-benzothiazole-2-thione;bis(5-nitro-1,3-benzothiazole-2-thiol)
• CAS NO: 58759-63-0
• Molecular Formula: C₇H₄N₂O₂S₂
• Molecular Weight: 212.25
• Product Categories: BENZOTHIAZOLE
• Mol File: 58759-63-0.mol
• Article Data: 9

Chemical Properties

• Melting Point: 223-225 °C
• Boiling Point: 380.6 °C at 760 mmHg
• Flash Point: 184 °C
• Appearance: /
• Density: 1.68 g/cm³
• Vapor Pressure: 5.38E-06mmHg at 25°C
• Refractive Index: 1.802
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.18±0.20(Predicted)
• CAS DataBase Reference: 2(3H)-Benzothiazolethione,5-nitro-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 2(3H)-Benzothiazolethione,5-nitro-(9CI)(58759-63-0)
• EPA Substance Registry System: 2(3H)-Benzothiazolethione,5-nitro-(9CI)(58759-63-0)

Safety Data

• Hazardous Substances Data: 58759-63-0(Hazardous Substances Data)

Usage

General Description

2(3H)-Benzothiazolethione,5-nitro-(9CI) is a chemical compound with the molecular formula C7H4N2O2S. It is a nitro-substituted derivative of benzothiazolethione, which is a heterocyclic compound containing both sulfur and nitrogen atoms. This chemical is commonly used in the synthesis of pharmaceuticals and agrochemicals due to its diverse biological activities, including antimicrobial, antiviral, and anti-inflammatory properties. It is also used as a building block in organic synthesis and can undergo various chemical reactions to form different derivatives. Additionally, it is known to have potential applications in the field of material science and as a fluorescent probe for metal ions. Overall, 2(3H)-Benzothiazolethione,5-nitro-(9CI) is a versatile compound with a wide range of uses in different industries.

InChI:InChI=1/C7H4N2O2S2/c10-9(11)4-1-2-6-5(3-4)8-7(12)13-6/h1-3H,(H,8,12)

Upstream product

• 10403-47-1 2-bromo 5-nitroaniline 
• 140-89-6 potassium ethyl xanthogenate 
• 369-36-8 6-fluoro-3-nitroaniline 
• 140-90-9 sodium O-ethyl dithiocarbonate 
• 75-15-0 carbon disulfide 
• 33240-96-9 3-nitroaniline hydrochloride 
• 99-09-2 3-nitro-aniline 
• 6283-25-6 H₂NC₆H₃(Cl)NO₂ 
• 89-37-2 dimethyl-dithiocarbamic acid-(2,4-dinitro-phenyl ester) 
• 97-00-7 1-chloro-2,4-dinitro-benzene 

Downstream Products

• 938112-27-7 C₁₄H₁₀NS₂NO₂ 
• 813424-06-5 C₈H₆N₂O₃S 
• 62386-22-5 5-nitro-3H-benzothiazol-2-one 
• 80945-82-0 2-chlorobenzo[d]thiazol-5-amine 
• 36894-61-8 N-(benzo[d]thiazol-5-yl)acetamide 
• 1123-93-9 5-aminobenzothiazole 
• 3622-38-6 2-chloro-5-nitro-benzothiazole 
• 2942-07-6 5-nitrobenzothiazole 

Relevant articles and documents

Small-compound enhancers for functional O-mannosylation of alpha-dystroglycan, and uses thereof

The present invention provides compounds that can enhance functional O-mannosylation of proteins including alpha-dystroglycan. Also provided are methods of preparation of the compounds defined by the formula I. Also provided are the methods of using the compounds or the pharmaceutical acceptable salts or prodrugs thereof in treating and preventing subjects suffering from the diseases including muscular dystrophies and cancers.

Synthesis and evaluation of some benzothiazole derivatives as antidiabetic agents

Objective: The objective of the present research investigation involves synthesis and biological evaluation of antidiabetic activity of benzothiazole derivatives. Methods: A novel series of benzothiazole derivatives 7(a-l) were synthesised and synthesised compounds were characterised for different physical and chemical properties like molecular formula, molecular weight, melting point, percentage yield, Rf value, IR,1HNMR,13CNMR and mass spectroscopy. The newly synthesised benzothiazole derivatives were subsequently assayed in vivo to investigate their hypoglycemic activity by the alloxan-induced diabetic model in rats. Results: All the synthesised derivatives showed significant biological efficacy. The compound 7d at 350 mg/kg exerted maximum glucose lowering effects whereas 7c showed minimum glucose lowering effects. All the compounds were effective, and experimental results were statistically significant at p0.01 and p0.05 level. Conclusion: From the results, it is clear that compound 7d demonstrated potent anti-diabetic activity and would be of better use in drug development to combat the metabolic disorder in future.

Small molecules enhance functional O-mannosylation of Alpha-dystroglycan

Alpha-dystroglycan (α-DG), a highly glycosylated receptor for extracellular matrix proteins, plays a critical role in many biological processes. Hypoglycosylation of α-DG results in various types of muscular dystrophies and is also highly associated with progression of majority of cancers. Currently, there are no effective treatments for those devastating diseases. Enhancing functional O-mannosyl glycans (FOG) of α-DG on the cell surfaces is a potential approach to address this unmet challenge. Based on the hypothesis that the cells can up-regulate FOG of α-DG in response to certain chemical stimuli, we developed a cell-based high-throughput screening (HTS) platform for searching chemical enhancers of FOG of α-DG from a large chemical library with 364,168 compounds. Sequential validation of the hits from a primary screening campaign and chemical works led to identification of a cluster of compounds that positively modulate FOG of α-DG on various cell surfaces including patient-derived myoblasts. These compounds enhance FOG of α-DG by almost ten folds, which provide us powerful tools for O-mannosylation studies and potential starting points for the development of drug to treat dystroglycanopathy.